Hinova Pharmaceuticals (SHSE:688302) Debt-to-Equity : 0.01 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Hinova Pharmaceuticals Debt-to-Equity?

Hinova Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥3.76 Mil. Hinova Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥9.21 Mil. Hinova Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥1,326.10 Mil. Hinova Pharmaceuticals's debt to equity for the quarter that ended in Mar. 2024 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Hinova Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

SHSE:688302' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.14 Med: 0.03 Max: 0.14
Current: 0.01

During the past 6 years, the highest Debt-to-Equity Ratio of Hinova Pharmaceuticals was 0.14. The lowest was -0.14. And the median was 0.03.

SHSE:688302's Debt-to-Equity is ranked better than
99.91% of 1060 companies
in the Biotechnology industry
Industry Median: 0.14 vs SHSE:688302: 0.01

Hinova Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Hinova Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hinova Pharmaceuticals Debt-to-Equity Chart

Hinova Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.14

0.12

0.02

0.01

Hinova Pharmaceuticals Quarterly Data
	Dec18	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial												0.03	0.03	0.03	0.01	0.01

Competitive Comparison of Hinova Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Hinova Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hinova Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hinova Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Hinova Pharmaceuticals's Debt-to-Equity falls into.

Hinova Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Hinova Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.768	+	9.08)	/	1367.09
	=	0.01

Hinova Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.758	+	9.21)	/	1326.103
	=	0.01

Hinova Pharmaceuticals (SHSE:688302) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Hinova Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Hinova Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Hinova Pharmaceuticals (SHSE:688302) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hinova Pharmaceuticals Inc (SHSE:688302) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 5 Keyuan South Road, No. 2 and 3, 4th Floor, Building 1, Rongyao Building, High-tech Zone, Sichuan Province, Chengdu, CHN, 610041

Website

http://www.hinovapharma.com

Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.

Hinova Pharmaceuticals (SHSE:688302) Headlines

No Headlines